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Abstract 
Objective: To compare the return-on-investment (ROI) of an integrated practice model 
versus a "hub and spoke" practice model of pharmacist provided medication therapy 
management (MTM).  
Methods: A cohort retrospective analysis of MTM claims billed in 76 pharmacies in 
North Carolina in the 2010 “hub and spoke” practice model and the 2012 “integrated” 
practice model were analyzed to calculate the ROI.  
Results: In 2010, 4,089 patients received an MTM resulting in 8,757 claims in the "hub 
and spoke" model. In 2012, 4,896 patients received an MTM resulting in 13,730 claims 
in the “integrated” model. In 2010, $165,897.26 was invested in pharmacist salary and 
$173,498.00 was received in reimbursement, resulting in an ROI of +$7,600.74 
(+4.6%). In 2012, $280,890.09 was invested in pharmacist salary and $302,963 was 
received in reimbursement, resulting in a ROI of +$22,072.91 or (+7.9%).  
Conclusion: The integrated model of MTM showed an increase in number of claims 
submitted and in number of patients receiving MTM services, ultimately resulting in a 
higher ROI. While a higher ROI was evident in the integrated model, both models 
resulted in positive ROI highlighting that MTM programs can be cost effective with 
different strategies of execution. 
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INTRODUCTION 
Community pharmacists own an opportunity for face-to-face interactions with 
patients at every medication fill.1,2  Many pharmacists have implemented programs to 
optimize these interactions with patients, namely through Medication Therapy 
Management (MTM) services. One service offered through MTM is the Comprehensive 
Medication Review (CMR), which consists of a full review of all medications and past 
medication history.1,2  If a medication problem is identified, a targeted medication review 
(TMR) will occur to resolve this specific medication-related problem.1,3,4   
When providing CMRs and TMRs pharmacists focus on optimal medication 
regimens to improve patient outcomes.2  The Asheville ProjectTM extensively evaluated 
the implementation of MTM and its effects on patient outcomes finding improvements in 
hypertension, dyslipidemia, asthma, and diabetes patients.5,6,7  Despite the benefits of 
increased patient interaction and data suggesting MTM correlates to increased patient 
outcomes, there is still a significant financial barrier to implementing MTM services.8,9,10   
A commonly used method to determine the financial impact of an MTM program 
is return on investment (ROI).  ROI represents revenue generated through MTM 
interventions versus investment in the MTM program.1,8,11  This is significant to obtain 
since 79% of pharmacies do not know their ROI and ROI is not typically used as a study 
parameter.1  It is important for pharmacists to be more cost conscious in order to meet 
the ever-increasing financial demands placed on community pharmacists and to 
encourage implementation of sustainable business models.1,8     
A regional chain pharmacy in North Carolina experimented with different MTM 
models. One model utilized was a “hub and spoke” model in which select pharmacists 
are hired to solely conduct MTM services for designated pharmacy locations.  Another 
model utilized was an “integrated” model in which all pharmacists conduct MTMs in their 
own pharmacy and community as part of the pharmacy workflow.  Currently, there is no 
literature published comparing the ROI of each model.  
 
OBJECTIVE 
The purpose of this study is to compare the ROI of two MTM practice models.   
 
METHODS 
This study was a multi-site, retrospective cohort analysis of 76 community 
pharmacies within a regional chain in North Carolina.  Patients who received a CMR or 
TMR in calendar years 2010 or 2012 were included. Revenue data generated from 
CMRs and TMRs were collected from a web-based MTM service provider. All paid 
claims were included. Excluded from analysis were non-paid claims and claims from the 
calendar year 2011, in which both models were deployed simultaneously. This study 
was approved by the University of North Carolina Institutional Review Board.   
Revenue associated with a TMR correlated to a $10 or $20 reimbursement. 
Revenue associated with a CMR correlated to a $50 or $75 reimbursement. Patient or 
prescriber refusals yielded $0 or $2 in reimbursement. 
The investment by the pharmacy was calculated using two elements: pharmacist 
average salary and average time for completion for MTM encounters. The average 
hourly salary in 2010 was $52.43, obtained from the regional pharmacy chain’s 
corporate office.4 The average hourly salary in 2012 was $54.54. This was estimated 
utilizing trends data from the National Community Pharmacist’s Association (NCPA) and 
the Bureau of Labor Statistics, which suggested a conservative 2% increase in salary 
from 2010-2011 and again from 2011-2012.12,13     
The average time for completion used to calculate ROI was 20 minutes for a 
TMR and 30 minutes for a CMR.  These values were designated after consultation with 
two MTM service providers for accepted practice.   
ANALYSIS 
          ROI was calculated for both the 2010 “hub and spoke” and 2012 “integrated” 
practice models by totaling each year’s revenue and subtracting total investment. 
Pharmacy revenue was calculated by tallying payment for the total number of CMRs 
and TMRs within each 12 month period (Table 1). Pharmacy investment was calculated 
by determining the total amount of time invested by pharmacists to conduct both TMRs 
and CMRs, in each model year, independently.  The total number of CMRs and TMRs 
completed each year were multiplied by 20 minutes and 30 minutes, respectively. The 
pharmacist average hourly salary for each model year was multiplied by the total 
amount of pharmacist time, in hours, invested to complete TMRs and CMRs reimbursed 
to the pharmacy.  
RESULTS 
     The “hub and spoke” model yielded 8,757 claims to 4089 patients resulting in 1471 
CMRs and 7286 TMRs. A total of 3164.17 pharmacist hours were invested, 735.5 
pharmacist hours to CMRs and 2428.67 hours to TMRs.  At $52.43 per hour, 
$165,897.26 was invested in MTM services for the “hub and spoke” model.  
Comparatively, the “integrated” model yielded 13,730 claims in total to 4896 patients, or 
3441 CMRs and 10289 TMRs. A total of 1720.5 pharmacist hours were invested in 
CMRs and 3429.67 pharmacist hours were invested in TMRs.  This resulted in a total of 
5150.17 pharmacist hours at $54.54 an hour investing $280.890.09 in MTM services for 
the “integrated” model (Table 1).   
     Pharmacy revenue through reimbursements was calculated by summing the 
reimbursements from the various types of CMRs and TMRs.  This resulted in a total 
reimbursement of $173,498.00 for the “hub and spoke” model and $302,963.00 for the 
“integrated” model (Table 1).  The “hub and spoke” yielded a net gain of $7,600.74 or a 
4.6% return on investment with the “hub and spoke” model.  Comparatively, the 
“integrated” model yielded a net gain of $22,072.91 or a 7.9% return on investment 
(Table 1). 
DISCUSSION 
    The integrated model of MTM resulted in a higher ROI than the traditional “hub and 
spoke” model.  Across 76 stores this equates, on average, to $100.00 net revenue per 
store in the hub and spoke model and $290.43 net revenue in the integrated model.  
Although such revenue would not be considered as a significant revenue source to 
individual pharmacy practices, the data demonstrate MTM services can provide revenue 
for the service.  This trial suggests that the additional pharmacy investment in 
pharmacist hours can be overcome by the reimbursements for services.  While both 
models of MTM presented a positive ROI, integrated models may have a greater 
potential for higher returns on investment by maximizing the efficiency of daily workflow, 
which may afford an opportunity to increase the number of patient encounters and thus 
reimbursable claims. 
     This is the first study looking at ROI for MTM services across a regional community 
pharmacy chain, showing feasibility and sustainability and contrasting different 
execution models of MTM.  A study by Truong et al.14 analyzed medication therapy 
management in a safety net clinic and found a high return on investment of 1:5 to 1:25.  
However, only 246 received MTM over 4 years, and results have limited translation to 
the community pharmacy setting.  McDonough et al.9 showed in one independent 
pharmacy that MTM services resulted in a net gain of $3.28.  The authors concluded a 
very modest ROI in one community pharmacy practice compared to the $100.00 per 
store in 2010 and $290.43 per store in 2012 found in the current study. Additional 
research is needed to determine long term sustainability of MTM services. 
LIMITATIONS 
     While confounding factors were minimized by study design, it is prudent to mention 
several limitations.  Firstly, direct observational data would have provided great insight 
into pharmacist “time for completion” for each MTM intervention. A prospective review 
should be considered to closely follow, rather than estimate, the exact time for 
completion of interventions made by pharmacists. 
      This study is also limited by the lack of ability to collect auxiliary revenue generated 
at the pharmacy, secondary to MTM services. These include new and refilled 
prescriptions, over-the-counter sales, and front-end items sold to the patient. 
Additionally, many of the community pharmacists in this analysis provided additional 
services including blood pressure screening and assessment, cholesterol and blood 
glucose point of care testing, and immunizations, all representing additional revenue 
sources. It is difficult to determine whether patients would have participated in the 
aforementioned revenue sources in response to pharmacist provided MTM services 
without purposeful and concurrent data collection. Lastly, the availability of MTM 
opportunities and reimbursement programs may limit the generalizability of the study 
due to large variances by state, region, payer, and contract year. 
CONCLUSION 
The integrated MTM model showed an increase in pharmacist provided MTM 
interventions resulting in a higher ROI. However, both models resulted in a positive ROI 
showing MTM services can be cost effective with varying practice models.  
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Table 1. Pharmacy Investment and Revenue 
MTM practice model Hub and Spoke Integrated 
Investments   
  Number of CMRs (pharmacist hours) 1471 (735.50) 3441 (1720.50) 
  Number of TMRs (pharmacist hours) 7286 (2428.67)  10289 (3429.67) 
  Total time invested by pharmacists 3164.17 5150.17 
  Average pharmacist salary $52.43 $54.54 
  Total expenditures $165,897.26 $280,890.09 
Revenue   
  CMR ($50) $70,700 $164,750 
  CMR ($75) $0 $525 
  TMR ($20) 
    Indication, efficacy, or safety 
$66,400 $74,360 
  TMR ($0 or $10) 
    Compliance 
$36,230 $63,230 
  TMR ($0 or $2) 
    Patient or prescriber refusal 
$168 $98 
  Total reimbursements $173,498.00 $302,963.00 
Return on Investment   
  ROI in dollars $7,600.74 $22,072.91 
  ROI percent change +4.6% +7.9% 
Key: CMRs, comprehensive medication reviews; TMRs, targeted medication 
reviews; ROI, return on investment 
 
	  
